FactSet Research Systems Stock To Go Ex-dividend Tomorrow (FDS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- The ex-dividend date for FactSet Research Systems (NYSE: FDS) is tomorrow, August 29, 2012. Owners of shares as of market close today will be eligible for a dividend of 31 cents per share. At a price of $92.82 as of 9:30 a.m. ET, the dividend yield is 1.3%.

The average volume for FactSet Research Systems has been 397,600 shares per day over the past 30 days. FactSet Research Systems has a market cap of $4.19 billion and is part of the technology sector and computer software & services industry. Shares are up 6.4% year to date as of the close of trading on Monday.

FactSet Research Systems Inc. provides financial and economic information to investment community worldwide. The company has a P/E ratio of 24.1, equal to the average computer software & services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates FactSet Research Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full FactSet Research Systems Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing